Survival of women with node negative breast cancer in the Auckland region

New Zealand Medical Journal

Volumn 109, Issue 1029, 1996, Pages 330-333

  Lethaby, Anne E ^b   Mason, Barbara H ^b   Harvey, Vernon J ^b   Holdaway, Ian M ^a,b  

^a Department of Endocrinology ^*

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGE; ARTICLE; BODY MASS; BREAST FEEDING; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LACTATION; LYMPH NODE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEW ZEALAND; PARITY; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; SURVIVAL RATE;

AGE FACTORS; BODY MASS INDEX; BREAST FEEDING; BREAST NEOPLASMS; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTATION; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEW ZEALAND; PARITY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 0030582240     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Valagussa P, Bonnadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 1170-8.
2. Fisher ER, Sass R, Fisher B and collaborating NSCBP investigators. Pathological findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X . Discriminants for 10th year treatment failure. Cancer 1984; 54: 712-23.
3. Anderson I, Aspegren K, Janzon L et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 943-8.
4. Fisher B, Redmond C, Dimitrov NV, et al. A randomised clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen-receptor-negative tumours. N Engl J Med 1989; 320: 473-96.
5. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15; 71-85.
6. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer - an intergroup study. N Engl J Med 1989; 320: 485-90.
7. The Ludwig Breast Cancer Study Group. Prolonged disease free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491-6.
8. Fisher B, Constantino V, Redmond C, et al. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor-positive tumours. N Engl J Med 1989; 320: 479-84.
9. McGuire WL. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989; 320: 525-7.
10. DeVita VT. Breast cancer therapy: exercising all our options. N Engl J Med 1989; 320: 527-9.
11. Holdaway IM, Mountjoy KG, Harvey VJ, et al. Clinical applications of receptor measurements in breast cancer. Br J Cancer 1980; 40: 136- 9.
12. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
13. Morabia A, Flandre P. Misclassification bias related to definition of menopausal status in case-control studies of breast cancer. Int J Epidem 1992; 21: 222-8.
14. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
15. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Rep 1966; 50, 163-70.
16. Cox DR. Regression models and life-tables. J Roy Stat Soc 1972; 34: 187-220.
17. Donegan WL. Are we positive about node negative breast cancer? (editorial). J Surg Oncol 1990; 43: 199-202.
18. Contesso G, Mouriesse H, Friedman S, et al. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378-86.
19. Delides GS, Garas G, Georgouli G, et al. Interlaboratory variations in the grading of breast cancer. Arch Pathol Lab Med 1982; 106: 126-8.
20. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-53.
21. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
22. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I and stage II breast carcinoma: a study of 644 patients with a median followup of 18 years. J Clin Oncol 1989; 7: 1239-51.
23. McNee RK, Mason BH, Neave LM, Kay RG. The influence of height, weight and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat 1987; 9: 145-50.
24. Thorpe SM, Rose C, Rasmussen BB. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Research 1987; 47: 6126-33.
25. Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982; 2: 171-6.
26. Valagussa P, Bignami P, Buzzoni R, et al. Are estrogen receptors alone a reliable prognostic factor in node negative breast cancer? In: SE Jones, SI Salmon, eds, Adjuvant therapy of cancer IV, London: Grune & Stratton, 1984: 407-515.
27. Butler JA, Bretsky S, Menendez-Botet C, et al. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 1985; 55: 1178-81.
28. Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M. Prognostic values of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. Eur J Cancer Clin Oncol; 25 (8): 1233-40.
29. Silvestrini R, Daidone MG, DiFronzo G, et al. Prognostic implication of labeling index versus estrogen receptors and tumour size in node-negative breast cancer. Breast Cancer Res Treat 1986; 7: 161-9.
30. Tandon AK, Clark GM, Chamnes GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297-302.
31. Hery M, Gioanni J, Lalanne CM, et al. The DNA labelling index: a prognostic factor in node negative breast cancer. Breast Cancer Res Treat 1987; 9: 207-11.
32. Clark GM, Owens MA, McGuire WL. A new S-phase model predicts recurrence for aneuploid as well as diploid node-negative breast cancer (abstract). Proc Am Soc Clin Oncol 1991; 10: 49.